Patent US5877007A successfully refreshed from Google Patents.
← Back to Patent Explorer
US5877007A Expired / Lapsed US ⏱️ 0.0 years remaining

Method of screening for protein inhibitors and activators

Assignee: Housey Pharmaceuticals Inc
•
Filing: 1995-06-07
•
Granted: 1999-03-02
•
Expires: 2015-06-07
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Cells useful in the pharmacological characterization of inhibitors or activators of proteins are provided. These cells a protein, the presence of which affects a particular characteristic of the cell which changes in response to substances which inhibit or activate the protein. Such responsive changes in a phenotypic characteristic may be utilized in many useful ways, including the discovery, development or characterization of substances suitable for the treatment of diseases or other conditions in human beings or animals. Such cells may also be useful for studying diseases or other biological processes, for determining the effects of various drugs alone or in combination, as well as for identifying or characterizing substances which may be useful in reducing or preventing the occurrence of a disease or other condition. Through the use of such cells in a cell based assay, tamoxifen is identified as an inhibitor of Protein Kinase C (PKC) activity in cell culture.

Inventors

  • 👤 Gerard Housey

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-05 14:59
CPC Classifications
C; C12; C12N; C12N9/00; C12N9/10; C12N9/12; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/5005; G01N33/5008; G01N33/5011; G01N33/502; G01N33/5026; G01N2333/00; G01N2333/435; G01N2333/705; G01N2333/82; G01N2333/90

Claims Analysis

Total Claims: 2
Claim 1
Independent Claim 207 words
A test cell in which there is present in the cell a target protein, wherein the presence of the target protein induces a change in a selected phenotypic characteristic of the test cell, other than the level of the target protein in the test cell, per se, wherein the change in the selected phenotypic characteristic is comparatively greater in the test cell than in a control cell, and wherein the change in the selected phenotypic characteristic has been found to be responsive to treatment with a test substance that is capable of inhibiting or activating a biochemical function of the target protein, by a method comprising the steps of: a) providing a test cell in which a target protein is present at a higher level relative to a control cell which produces the protein at a lower level or essentially does not produce the protein; b) treating the test cell of step (a) containing the target protein of step (a) with a test substance; and c) examining the treated test cell of step (b) to determine whether an selected phenotypic characteristic that is responsive to inhibition or activation of the target protein of step (a) has been altered by treatment with the test substance of step (b).
Claim 2
Dependent Claim 207 words
A test cell in which there is present in the cell a target protein, wherein the presence of the target protein induces a change in a selected phenotypic characteristic of the test cell, other than the level of the target protein in the test cell, per se, wherein the change in the selected phenotypic characteristic is comparatively greater in the test cell than in a control cell, and wherein the change in the selected phenotypic characteristic has been found to be responsive to treatment with a test substance that is capable of inhibiting or activating a biochemical function of the target protein, by a method comprising the steps of: a) providing a test cell in which a target protein is present at a higher level relative to a control cell which produces the protein at a lower level or essentially does not produce the protein; b) treating the test cell of step (a) containing the target protein of step (a) with a test substance; and c) examining the treated test cell of step (b) to determine whether an selected phenotypic characteristic that is responsive to inhibition or activation of the target protein of step (a) has been altered by treatment with the test substance of step (b).

References Cited (Backward Citations)

US4981790A Cited
US4980281A Cited
US5266464A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2002-03-01 2002-08-31 2003-03-02 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2006-03-01 2006-08-31 2007-03-02 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2010-03-01 2010-08-31 2011-03-02 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag